PADI2

Across TCGA pan-cancer cohorts, PADI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PADI2 data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PADI2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PADI2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where PADI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.837	.001	40	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.726	.018	7	view →
CCRCC	DFS	Quartile	III,IV	0.050	0.714	.038	3	view →
PDAC	OS	Tertile	III,IV	0.600	1.000	.049	1	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PADI2–UCEC (OS)

Open the UCEC breakdown →